China National Accord Medicines Corporation: Announcement of the implementation of equity distribution in 2023.
Sinopharm\'s agreement: announcement on the 2023 profit distribution plan
Sinopharm: 2022 Equity Distribution Implementation Notice
Sinopharm Consistent: Announcement on 2022 Profit Distribution and Capital Transfer Plan from Capital Provident Fund
Sinopharm: 2021 Equity Distribution Implementation Notice
Sinopharm Consistent: Report on Asset Sales, Issuance of Shares, and Payment of Cash to Purchase Assets and Raise Supporting Funds and Related Transactions (Revised Draft)
Sinopharm Consistent: Summary of the Report on Asset Sales, Issuance of Shares, and Payment of Cash to Purchase Assets and Raise Supporting Funds and Related Transactions (Revised Draft)
Sinopharm Consistent: Notice on Revised Instructions for Asset Sales, Issuance of Shares and Payment of Cash to Purchase Assets and Raise Supporting Funds and Related Transactions and Restructuring Reports
Sinopharm agreed: Announcement on asset sales, issuance of shares, and payment of cash to purchase assets and raise supporting funds and related transactions was officially approved by the China Securities Regulatory Commission
Sinopharm Consistent: Report on Asset Sales, Issuance of Shares, and Payment of Cash to Purchase Assets and Raise Supporting Funds and Related Transactions (Draft) (Three Revisions)
Sinopharm Consistent: Report on Asset Sales, Issuance of Shares, and Payment of Cash to Purchase Assets and Raise Supporting Funds and Related Transactions (Draft) (Second Revision)
Sinopharm Consistent: Notice on Revised Instructions for Asset Sales, Issuance of Shares and Payment of Cash to Purchase Assets and Raise Supporting Funds and Related Transactions and Restructuring Reports
Sinopharm Consistent: Report on Asset Sales, Issuance of Shares, and Payment of Cash to Purchase Assets and Raise Supporting Funds and Related Transactions (Draft) (Revised Draft)
Sinopharm Consistent: Asset Sales, Issuance of Shares, and Payment of Cash to Purchase Assets and Raise Supporting Funds and Related Transactions Report (Draft) Summary
Sinopharm is consistent: reports on asset sales, issuance of shares, and payment of cash to purchase assets and raise supporting funds and related transactions (draft)
Sinopharm is consistent: Profit prediction compensation agreement between Shanghai Hyundai Pharmaceutical Co., Ltd. and the company to issue shares to purchase assets (1)
Sinopharm agreed: supplementary agreement between Shanghai Hyundai Pharmaceutical Co., Ltd. and the company to issue shares to purchase assets
Sinopharm is consistent: Profit prediction compensation agreement between Shanghai Hyundai Pharmaceutical Co., Ltd. and the company to issue shares to purchase assets (3)
Sinopharm is consistent: Profit prediction compensation agreement between Shanghai Hyundai Pharmaceutical Co., Ltd. and the company to issue shares to purchase assets (2)
Sinopharm Consistent: Profit Forecast Compensation Agreement for Issuing Shares to Purchase Assets (2)
No Data